Carboplatin Treatment Options in United Kingdom

A collection of 302 research studies where Carboplatin is the interventional treatment. These studies are located in the United Kingdom . Carboplatin is used for conditions such as Non-Small Cell Lung Cancer, Ovarian Cancer and Lung Cancer.

Home

United Kingdom

All Treatments

Carboplatin

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

NCT00021255

Completed

Primary objective: * Compare disease-free survival in women with human epidermal growth factor receptor 2 (HER2)-neu-expressing node-positive or high-risk node-negative operable breast cancer treated with adjuvant doxorubicin, cyclophosphamide, and docetaxel with or without trastuzumab (Herceptin) vs trastuzumab, docetaxel, and carboplatin. Secondary objective: * Compare overall survival of participants treated with these regimens. * Compare the toxic effects (including cardiac) of these regi... Read More

Gender:

FEMALE

Ages:

Between 18 years and 70 years

Trial Updated:

09/26/2016

Locations: Sanofi-Aventis Administrative Office, Bridgewater, New Jersey +41 locations

Sanofi-Aventis Administrative Office, Bridgewater, New Jersey

Sanofi-Aventis Administrative Office, Buenos Aires, Not set

Sanofi-Aventis Administrative Office, Macquarie Park, Not set

Sanofi-Aventis Administrative Office, Vienna, Not set

Sanofi-Aventis Administrative Office, Diegem, Not set

Sanofi-Aventis Administrative Office, Sarajevo, Not set

Sanofi-Aventis Administrative Office, Sao Paulo, Not set

Sanofi-Aventis Administrative Office, Vazrjdane Region, Not set

Sanofi-Aventis Administrative Office, Québec, Not set

Sanofi-Aventis Administrative Office, Bogota, Not set

Sanofi-Aventis Administrative Office, Zagreb, Not set

Sanofi-Aventis Administrative Office, Praha, Not set

Sanofi-Aventis Administrative Office, Cairo, Not set

Sanofi-Aventis Administrative Office, Tallin, Not set

Sanofi-Aventis Administrative Office, Paris, Not set

Sanofi-Aventis Administrative Office, Frankfurt, Not set

Sanofi-Aventis Administrative Office, Kallithea, Not set

Sanofi-Aventis Administrative Office, Hong Kong, Not set

Sanofi-Aventis Administrative Office, Budapest, Not set

Sanofi-Aventis Administrative Office, Mumbai, Not set

Sanofi-Aventis Administrative Office, Dublin, Not set

Sanofi-Aventis Administrative Office, Natanya, Not set

Sanofi-Aventis Administrative Office, Milan, Not set

Sanofi-Aventis Administrative Office, Seoul, Not set

Sanofi-Aventis Administrative Office, Beirut, Not set

Sanofi-Aventis Administrative Office, Col. Coyoacan, Not set

Sanofi-Aventis Administrative Office, Macquarie Park, Not set

Sanofi-Aventis Administrative Office, Warsaw, Not set

Sanofi-Aventis Administrative Office, Bucuresti, Not set

Sanofi-Aventis Administrative Office, Moscow, Not set

Sanofi-Aventis Administrative Office, Bratislava, Not set

Sanofi-Aventis Administrative Office, Ljubljana, Not set

Sanofi-Aventis Administrative Office, Gauteng, Not set

Sanofi-Aventis Administrative Office, Barcelona, Not set

Sanofi-Aventis Administrative Office, Bromma, Not set

Sanofi-Aventis Administrative Office, Genève, Not set

Sanofi-Aventis Administrative Office, Taipei, Not set

Sanofi-Aventis Administrative Office, Megrine, Not set

Sanofi-Aventis Administrative Office, Istanbul, Not set

Sanofi-Aventis Administrative Office, Guildford Surrey, Not set

Sanofi-Aventis Administrative Office, Montevideo, Not set

Sanofi-Aventis Administrative Office, Caracas, Not set

Conditions: Breast Neoplasms

Learn More ›

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

NCT01496742

Completed

This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of RO5490258 (MetMab) in combination with either of two backbone chemotherapy regimens in the first-line setting in patients with incurable Stage IIIB or IV non-squamous non-small cell lung cancer. In Cohort 1, patients will be randomized to receive 4 cycles of bevacizumab (Avastin) 15 mg/kg iv, paclitaxel 200 mg/m2 iv, platinum (cisplatin/carboplatin) iv plus either MetMab 15 mg/kg iv or p... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

09/21/2016

Locations: Not set, Huntsville, Alabama +86 locations

Not set, Huntsville, Alabama

Not set, Scottsdale, Arizona

Not set, Bakersfield, California

Not set, Fullerton, California

Not set, Los Angeles, California

Not set, Northridge, California

Not set, San Luis Obispo, California

Not set, Santa Barbara, California

Not set, Stanford, California

Not set, Grand Junction, Colorado

Not set, Boynton Beach, Florida

Not set, Hollywood, Florida

Not set, Orlando, Florida

Not set, Lawrenceville, Georgia

Not set, Marietta, Georgia

Not set, Harvey, Illinois

Not set, Fort Wayne, Indiana

Not set, Indianapolis, Indiana

Not set, Muncie, Indiana

Not set, Metairie, Louisiana

Not set, Minneapolis, Minnesota

Not set, Las Vegas, Nevada

Not set, New York, New York

Not set, Hickory, North Carolina

Not set, Cleveland, Ohio

Not set, Columbus, Ohio

Not set, Middletown, Ohio

Not set, Bend, Oregon

Not set, Portland, Oregon

Not set, Seattle, Washington

Not set, Buenos Aires, Not set

Not set, La Rioja, Not set

Not set, Santa Rosa, Not set

Not set, Grenoble, Not set

Not set, Paris, Not set

Not set, Rennes, Not set

Not set, Göttingen, Not set

Not set, Halle (Saale), Not set

Not set, Immenhausen, Not set

Not set, München, Not set

Not set, Münster, Not set

Not set, Afula, Not set

Not set, Ashkelon, Not set

Not set, Holon, Not set

Not set, Tel Aviv, Not set

Not set, Zerifin, Not set

Not set, Avellino, Campania

Not set, Udine, Friuli-Venezia Giulia

Not set, Roma, Lazio

Not set, Cremona, Lombardia

Not set, Milano, Lombardia

Not set, Orbassano, Piemonte

Not set, Daugavpils, Not set

Not set, Liepaja, Not set

Not set, Riga, Not set

Not set, Kuala Lumpur, Not set

Not set, Negeri Sembilan, Not set

Not set, Penang, Not set

Not set, Pulau Pinang, Not set

Not set, Tanjung Bungah, Not set

Not set, Aguascalientes, Not set

Not set, Chihuahua, Not set

Not set, Leon, Not set

Not set, CEBU City, Not set

Not set, Davao City, Not set

Not set, Pasig City, Not set

Not set, Quezon City, Not set

Not set, Pamplona, Navarra

Not set, Barcelona, Not set

Not set, Madrid, Not set

Not set, Zaragoza, Not set

Not set, Kaohsiung, Not set

Not set, Taichung, Not set

Not set, Tainan, Not set

Not set, Taipei, Not set

Not set, Aberdeen, Not set

Not set, Birmingham, Not set

Not set, Bournemouth, Not set

Not set, Leeds, Not set

Not set, Manchester, Not set

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Learn More ›

A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

NCT01519804

Completed

This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with paclitaxel plus platinum in patients with incurable Stage IIIB or Stage IV squamous non-small cell lung cancer (NSCLC). Patients will be randomized to receive either onartuzumab (MetMAb) 15 mg/kg iv or placebo on Day 1 of each 21-day cycle in combination with 4 cycles of paclitaxel 200 mg/m2 iv and platinum (carboplatin/cisplatin) iv on Day 1 of e... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

09/01/2016

Locations: Not set, Huntsville, Alabama +68 locations

Not set, Huntsville, Alabama

Not set, Scottsdale, Arizona

Not set, Bakersfield, California

Not set, Fullerton, California

Not set, Los Angeles, California

Not set, Northridge, California

Not set, Sacramento, California

Not set, San Luis Obispo, California

Not set, Santa Barbara, California

Not set, Stanford, California

Not set, Grand Junction, Colorado

Not set, Boynton Beach, Florida

Not set, Orlando, Florida

Not set, Weston, Florida

Not set, Marietta, Georgia

Not set, Chicago, Illinois

Not set, Harvey, Illinois

Not set, Fort Wayne, Indiana

Not set, Indianapolis, Indiana

Not set, Muncie, Indiana

Not set, Metairie, Louisiana

Not set, Boston, Massachusetts

Not set, Minneapolis, Minnesota

Not set, St. Louis, Missouri

Not set, Las Vegas, Nevada

Not set, Hickory, North Carolina

Not set, Cleveland, Ohio

Not set, Middletown, Ohio

Not set, Bend, Oregon

Not set, Pittsburgh, Pennsylvania

Not set, Seattle, Washington

Not set, Buenos Aires, Not set

Not set, La Rioja, Not set

Not set, Santa Rosa, Not set

Not set, Grenoble, Not set

Not set, Lyon, Not set

Not set, Paris, Not set

Not set, Rennes, Not set

Not set, Berlin, Not set

Not set, Göttingen, Not set

Not set, Halle (Saale), Not set

Not set, Immenhausen, Not set

Not set, München, Not set

Not set, Münster, Not set

Not set, Afula, Not set

Not set, Ashkelon, Not set

Not set, Tel Aviv, Not set

Not set, Zerifin, Not set

Not set, Avellino, Campania

Not set, Napoli, Campania

Not set, Udine, Friuli-Venezia Giulia

Not set, Cremona, Lombardia

Not set, Milano, Lombardia

Not set, Daugavpils, Not set

Not set, Liepaja, Not set

Not set, Riga, Not set

Not set, Pamplona, Navarra

Not set, Barcelona, Not set

Not set, Madrid, Not set

Not set, Zaragoza, Not set

Not set, Aberdeen, Not set

Not set, Birmingham, Not set

Not set, Bournemouth, Not set

Not set, Leeds, Not set

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Learn More ›

Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium

NCT02866370

Unknown

The trial will recruit up to 120 patients; 90 with ovarian clear cell carcinoma and up to 30 with endometrial clear cell carcinoma. Patients will be randomised between chemotherapy and Nintedanib 200mg twice daily oral administration (PO) continuously. The primary diagnosis must be histologically confirmed and central pathological review of the presenting tumour or biopsy of relapsed disease must find at least 50% clear cell carcinoma with no serous differentiation

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

08/10/2016

Locations: Beatson West of Scotland Cancer Centre, Glasgow, Lanarkshire +16 locations

Conditions: Ovarian Clear Cell Carcinoma, Endometrial Clear Cell Carcinoma

Learn More ›

A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)

NCT00682981

Completed

The Phase I portion of this protocol will determine the best phase II dose and schedule of obatoclax with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. The Phase II portion will evaluate the response rate to this regimen.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/19/2016

Locations: Clearview Cancer Institute, Huntsville, Alabama +74 locations

Clearview Cancer Institute, Huntsville, Alabama

Northwest Alabama Cancer Center, Muscle Shoals, Alabama

Mayo Clinic-Arizona, Scottsdale, Arizona

Arizona Clinical Research Center, Tucson, Arizona

City of Hope and Beckman Research Institute, Duarte, California

University of California-San Diego Moores Cancer Center, LaJolla, California

Georgetown University Hospital-Lombardi Comprehensive Cancer Center, Washington, District of Columbia

Integrated Community Oncology Network, Jacksonville, Florida

University of Miami-Sylvester Cancer Center, Miami, Florida

Florida Cancer Institute, New Port Richey, Florida

H. Lee Moffitt Cancer Center, Tampa, Florida

Northwest Georgia Oncology Centers, Marietta, Georgia

University of Chicago, Chicago, Illinois

Iowa Blood and Cancer Center, PLC, Cedar Rapids, Iowa

Cancer Center of Kansas, Wichita, Kansas

James Brown Cancer Center, Louisville, Kentucky

Center for Cancer and Blood Disorders, Bethesda, Maryland

Kalamazoo Hematology and Oncology, Kalamazoo, Michigan

Mid Ohio Oncology/Hematology, Inc., Columbus, Ohio

Cancer Care Associates-Oklahoma City, Oklahoma City, Oklahoma

Cancer Care Associates-Tulsa, Tulsa, Oklahoma

University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania

Greater Philadelphia Cancer and Hematology Specialists, Philadelphia, Pennsylvania

Cancer Centers of the Carolinas, Greenville, South Carolina

McLeod Cancer & Blood Center, Johnson City, Tennessee

The West Clinic, Memphis, Tennessee

Baylor, Dallas, Texas

UT Southwestern Medical Center at Dallas, Dallas, Texas

Tyler Cancer Center, Tyler, Texas

Peninsula Cancer Institute, Newport News, Virginia

Virginia Oncology Associates, Norfolk, Virginia

Wheeling Hospital, Wheeling, West Virginia

MHAT "Dr. Tota Venkova", Gabrovo, Not set

District Dispensary for Cancer Diseases, Plovdiv, Plovdiv, Not set

District Dispensary for Oncology Diseases, Sofia City, Sofia, Not set

Specialized Hospital for Active Treatment in Oncology, Sofia, Not set

Tom Baker Cancer Centre, Calgary, Alberta

Cross Cancer Institute, Edmonton, Alberta

McGill University, Montreal, Quebec

Regional Hospital Kladno, Kladno, Not set

Hospital Kutna Hora, Kutna Hora, Not set

University Hospital Olomouc, Olomouc, Not set

Faculty Hospital Ostrava, Ostrava-Poruba, Not set

University Hospital Na Bulovce, Prague, Not set

National Institute of Tuberculosis & Pulmonology, Budapest, Not set

Semmelweis University Medical School, Budapest, Budapest, Not set

University Of Debrecen Medical and Health Science Centre, Debrecen, Not set

Csongrad County Council's Hospital for Chest Diseases, Deszk, Not set

Bacs-Kiskun County Hospital, Kecskemet, Not set

State Hospital Matrahaza, Matrahaza, Not set

Clinfan Ltd. SMO Tolna County Hospital, Szekszard, Not set

Pest County Hospital, Torokbalint, Not set

Vedanta Institute of Medical Sciences, Ahmedabad, Gujarat

Kailash Cancer Hospital and Research Centre, Goraj, Gujarat

Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, Madhya Pradesh

Curie Manavata Cancer Centre, Nashik, Maharashtra

Noble Hospital, Pune, Maharashtra

Dr. Kamakshi Memorial Hospital, Chennai, Tamal Nadu

Galaxy Cancer Institute, Pushpanjali Crosslay Hospital, Ghaziabad, Uttar Pradesh

Orchid Nursing Home, Kolkata, West Bengal

Wojewodzki Szpital Specjalistyczny im. K. Dluskiego, Bialystok, Not set

SPZ Gruzlicy i Chorob Pluc, Olsztyn, Not set

Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy, Otwock, Not set

Specjalistyczny Szpital im Prof Alfreda Sokolowskiego, Szczecin-Zdunowo, Not set

Wojewodzki Szpital Chorob Pluc, Wodzislaw Slaski, Not set

Prof. Dr. Ion Chiricuta Oncology Institute Cluj Napoca, Cluj, Not set

Oncology Medical Centre SCM, Iasi, Not set

Emergency Clinical County Hospital Oradea, Oradea, Not set

Center for Pulmonary Diseases, Clinic for Internal Medicine, Kragujevac, Not set

Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Not set

Northern Ireland Cancer Centre Queens University Belfast, Belfast, Northern Ireland

Royal Bournemouth Hospital, Dorset, Not set

Nottingham University Hospital, Nottingham, Not set

Weston Park Hospital, Sheffield, Not set

Royal Surrey County Hospital, Surrey, Not set

Conditions: Extensive-stage Small Cell Lung Cancer

Learn More ›

OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer

NCT00382811

Completed

The purpose of this project is to see if weekly carboplatin compared with phenoxodiol in combination with weekly carboplatin, is effective against late stage ovarian cancer and to see what, if any, side-effects of treatment may result.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

07/13/2016

Locations: Arizona Clinical Research Center, Inc., Tuscon, Arizona +69 locations

Arizona Clinical Research Center, Inc., Tuscon, Arizona

Glendale Adventist, Glendale, California

Kaiser Permanente Los Angeles Medical Center, Los Angeles, California

Cedars-Sinai Medical Center, Los Angeles, California

Gynecology Oncology Associates, Newport Beach, California

Yale University School of Medicine, New Haven, Connecticut

Hematology Oncology, PC (Carl and Dorothy Bennett Cancer Center), Stamford, Connecticut

Gynecologic Oncology Associates, Pembroke Pines, Florida

Piedmont Hospital, Atlanta, Georgia

Medical College of Georgia Cancer Center, Augusta, Georgia

Associates in Women's Health, Wichita, Kansas

Hematology and Oncology Specialists, LLC, Metairie, Louisiana

Greater Baltimore Medical Centre, Baltimore, Maryland

Gynecologic Oncology of West Michigan, Grand Rapids, Michigan

Providence Hospital and Medical Centers, Southfield, Michigan

The Center for Cancer & Hematological Disease, Cherry Hill, New Jersey

Jersey Shore Medical Center, Neptune, New Jersey

The University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico

Schwartz Gynecologic Oncology, Brightwaters, New York

New York Downtown Hospital, New York, New York

University of Rochester Gynecologic Oncology Associates, Rochester, New York

Carolinas Medical Center, Charlotte, North Carolina

Brody School of Medical at East Carolina University, Greenville, North Carolina

Wake Forest University Health Sciences, Winston-Salem, North Carolina

Gabrail Cancer Center, Canton, Ohio

MetroHealth Medical Center, Cleveland, Ohio

OSU James Cancer Hospital & Solove Research Institute, Columbus, Ohio

Miami Valley Hospital, Dayton, Ohio

Chattanooga GYN Oncology, Chattanooga, Tennessee

Chattanooga's Program In Women's Oncology, Chattanooga, Tennessee

Hall and Martin MDS, P.C., Knoxville, Tennessee

Sarah Cannon Research Institute, Nashville, Tennessee

Hope Cancer Clinic, Brownsville, Texas

University of Texas Southwestern Medical Center Simmons Comprehensive Cancer Center, Dallas, Texas

Baylor College of Medicine, Houston, Texas

Northern Virginia Pelvic Surgery Associates, Annadale, Virginia

Virginia Mason Medical Center Department of Hematology/Oncology, Seattle, Washington

Prince of Wales Hospital, Randwick, New South Wales

Royal North Shore Hospital, Sydney, New South Wales

Westmead Hospital, Westmead, New South Wales

Mater Adult Hospital, Brisbane, Queensland

Royal Adelaide Hospital, Adelaide, South Australia

UZ Antwerpen, Edegem, Not set

UZ Leuven, Leuven, Not set

IEO- Istituto Europeo di Oncologia, Milano, Not set

Istitutio Fisioterapici Ospitaleri, Roma, Not set

Bialostockie Centrum Onkologii im. Marii Sklodowskiej-Curie Oddzial Onkologii Ginekologicznej, Bialystok, Not set

Ackademickie Centrum Kliniczne-Szpital, Akademii Medycznej w Gdansku, Gdansk, Not set

Centrum Onkologii-Instytut im. M. Sklodowskiej-Curie, Oddzial w Gliwicach, Gliwice, Not set

Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie Oddzial w Krakowie Klinika Ginekologii Onkologicznej, Krakow, Not set

Centrum Onkologii Ziemi, Lublin, Not set

Ginekologiczno - Polozniczy Szpital Kliniczny AM im. K. Marcinkowskiego w Poznaniu SPZOZ Klinika Onkologii Ginekologicznej, Poznan, Not set

Centrum Onkologii-Instytut im. M. Sklodowskiej Curie Klinika Nowotworow Narzadow Plciowych Kobiecych, Warszawa, Not set

Hospital Germans Trias i Pujol, Badalona, Barcelona

Hospital General Universitario de Alicante, Alicante, Not set

Hospital del Mar, Barcelona, Not set

Hospital General Vall d'Hebron, Barcelona, Not set

Hospital Clinic i Provincial de Barcelona, Barcelona, Not set

Hospital General Universitario de Valencia, Valencia, Not set

Yeovil District Hospital, Yeovil, Somerset

Cancer Research UK Clinical Trials Unit Old Clinical Investigations Building, Birmingham, Not set

Ninewells Hospital, Dundee, Not set

Edinburgh Cancer Research Centre Western General Hospital, Edinburgh, Not set

The Beatson West of Scotland Cancer Centre, Glasgow, Not set

St James University Hospital, Leeds, Not set

Hammersmith Hospital, London, Not set

Cancer Research UK & UCL Cancer Trials Center, London, Not set

Nottingham University Hospitals NHS Trust, Nottingham, Not set

Royal Marsden NHS Foundation Trust, Sutton, Not set

Clatterbridge Centre for Oncology, Wirral, Not set

Conditions: Fallopian Tube Cancer, Peritoneal Neoplasms, Ovarian Cancer

Learn More ›

Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer

NCT00686959

Completed

This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/20/2016

Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama +132 locations

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama

Conditions: Non Small Cell Lung Cancer

Learn More ›

Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)

NCT01082549

Completed

To evaluate the overall survival (OS) of patients with advanced squamous cell lung cancer receiving the combination of gemcitabine/carboplatin either with or without Iniparib. Based on data generated by BiPar/Sanofi, it is concluded that iniparib does not possess characteristics typical of the PARP inhibitor class. The exact mechanism has not yet been fully elucidated, however based on experiments on tumor cells performed in the laboratory, iniparib is a novel investigational anti-cancer agent... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/17/2016

Locations: Investigational Site Number 840306, Birmingham, Alabama +141 locations

Investigational Site Number 840306, Birmingham, Alabama

Investigational Site Number 840207, Huntsville, Alabama

Investigational Site Number 840351, Muscle Shoals, Alabama

Investigational Site Number 840338, Anaheim, California

Investigational Site Number 840353, Burbank, California

Investigational Site Number 840341, Concord, California

Investigational Site Number 840317, Duarte, California

Investigational Site Number 840339, La Verne, California

Investigational Site Number 840309, Loma Linda, California

Investigational Site Number 840307, Los Angeles, California

Investigational Site Number 840327, Maywood, California

Investigational Site Number 840303, San Diego, California

Investigational Site Number 840321, Santa Rosa, California

Investigational Site Number 840326, Stockton, California

Investigational Site Number 840310, Vallejo, California

Investigational Site Number 840336, Denver, Colorado

Investigational Site Number 840346, Norwich, Connecticut

Investigational Site Number 840315, Newark, Delaware

Investigational Site Number 840216, Ft. Lauderdale, Florida

Investigational Site Number 840215, Jacksonville, Florida

Investigational Site Number 840217, Lakeland, Florida

Investigational Site Number 840205, Orlando, Florida

Investigational Site Number 840104, Sarasota, Florida

Investigational Site Number 840343, Athens, Georgia

Investigational Site Number 840213, Augusta, Georgia

Investigational Site Number 840347, Augusta, Georgia

Investigational Site Number 840201, Gainesville, Georgia

Investigational Site Number 840301, Lawrenceville, Georgia

Investigational Site Number 840305, Marietta, Georgia

Investigational Site Number 840314, Tucker, Georgia

Investigational Site Number 840313, Chicago, Illinois

Investigational Site Number 840218, Evansville, Indiana

Investigational Site Number 840319, Indianapolis, Indiana

Investigational Site Number 840329, South Bend, Indiana

Investigational Site Number 840316, Wichita, Kansas

Investigational Site Number 840320, Louisville, Kentucky

Investigational Site Number 840308, Scarborough, Maine

Investigational Site Number 840202, Bethesda, Maryland

Investigational Site Number 840345, Salisbury, Maryland

Investigational Site Number 840337, Royal Oak, Michigan

Investigational Site Number 840328, St. Louis Park, Minnesota

Investigational Site Number 840210, Bridgeton, Missouri

Investigational Site Number 840212, Omaha, Nebraska

Investigational Site Number 840318, Las Vegas, Nevada

Investigational Site Number 840204, Morristown, New Jersey

Investigational Site Number 840350, Chapel Hill, North Carolina

Investigational Site Number 840330, Durham, North Carolina

Investigational Site Number 840105, Cincinnati, Ohio

Investigational Site Number 840302, Cleveland, Ohio

Investigational Site Number 840348, Cleveland, Ohio

Investigational Site Number 840335, Columbus, Ohio

Investigational Site Number 840311, Bend, Oregon

Investigational Site Number 840211, West Reading, Pennsylvania

Investigational Site Number 840352, Charleston, South Carolina

Investigational Site Number 840106, Columbia, South Carolina

Investigational Site Number 840220, Spartanburg, South Carolina

Investigational Site Number 840103, Chattanooga, Tennessee

Investigational Site Number 840208, Chattanooga, Tennessee

Investigational Site Number 840203, Collierville, Tennessee

Investigational Site Number 840101, Nashville, Tennessee

Investigational Site Number 840323, Fort Worth, Texas

Investigational Site Number 840219, Newport News, Virginia

Investigational Site Number 840102, Richmond, Virginia

Investigational Site Number 840312, Seattle, Washington

Investigational Site Number 840344, Tacoma, Washington

Investigational Site Number 840322, Morgantown, West Virginia

Investigational Site Number 840331, Wauwatosa, Wisconsin

Investigational Site Number 056004, Brugge, Not set

Investigational Site Number 056003, Brussel, Not set

Investigational Site Number 056001, Liège, Not set

Investigational Site Number 124003, Edmonton, Not set

Investigational Site Number 124006, Greenfield Park, Not set

Investigational Site Number 124005, London, Not set

Investigational Site Number 124007, Oshawa, Not set

Investigational Site Number 124004, Quebec, Not set

Investigational Site Number 124001, Toronto, Not set

Investigational Site Number 250007, Brest, Not set

Investigational Site Number 250002, Dijon, Not set

Investigational Site Number 250009, Limoges Cedex, Not set

Investigational Site Number 250003, Marseille, Not set

Investigational Site Number 250004, Paris Cedex 13, Not set

Investigational Site Number 250010, Pierre Benite Cedex, Not set

Investigational Site Number 250008, Poitiers, Not set

Investigational Site Number 250001, Saint-Herblain Cedex, Not set

Investigational Site Number 250006, Strasbourg, Not set

Investigational Site Number 250005, Tours Cedex 1, Not set

Investigational Site Number 276002, Amberg, Not set

Investigational Site Number 276004, Berlin, Not set

Investigational Site Number 276007, Frankfurt Am Main, Not set

Investigational Site Number 276008, Großhansdorf, Not set

Investigational Site Number 276010, Halle/Saale, Not set

Investigational Site Number 276012, Heidelberg, Not set

Investigational Site Number 276009, Immenhausen, Not set

Investigational Site Number 276001, Löwenstein, Not set

Investigational Site Number 276006, München, Not set

Investigational Site Number 276003, Oldenburg, Not set

Investigational Site Number 348005, Budapest, Not set

Investigational Site Number 348003, Budapest, Not set

Investigational Site Number 348001, Mátraháza, Not set

Investigational Site Number 348004, Nyíregyháza, Not set

Investigational Site Number 376002, Kfar Saba, Not set

Investigational Site Number 376005, Petah-Tikva, Not set

Investigational Site Number 376003, Tel Hashomer, Not set

Investigational Site Number 376001, Tzrifin, Not set

Investigational Site Number 380006, Genova, Not set

Investigational Site Number 380001, Novara, Not set

Investigational Site Number 380008, Orbassano, Not set

Investigational Site Number 380002, Perugia, Not set

Investigational Site Number 380003, Roma, Not set

Investigational Site Number 380007, Roma, Not set

Investigational Site Number 442001, Luxembourg, Not set

Investigational Site Number 528005, Breda, Not set

Investigational Site Number 528004, Eindhoven, Not set

Investigational Site Number 528001, Groningen, Not set

Investigational Site Number 528006, Maastricht, Not set

Investigational Site Number 528003, Zwolle, Not set

Investigational Site Number 616006, Bialystok, Not set

Investigational Site Number 616001, Krakow, Not set

Investigational Site Number 616007, Lubin, Not set

Investigational Site Number 616004, Olsztyn, Not set

Investigational Site Number 616008, Torun, Not set

Investigational Site Number 616002, Warszawa, Not set

Investigational Site Number 616005, Wroclaw, Not set

Investigational Site Number 642002, Alba Iulia, Not set

Investigational Site Number 642006, Bucuresti, Not set

Investigational Site Number 642001, Cluj Napoca, Not set

Investigational Site Number 642004, Craiova, Not set

Investigational Site Number 642005, Hunedoara, Not set

Investigational Site Number 724009, Badalona, Not set

Investigational Site Number 724003, Barcelona, Not set

Investigational Site Number 724004, La Coruña, Not set

Investigational Site Number 724005, Madrid, Not set

Investigational Site Number 724006, Madrid, Not set

Investigational Site Number 724002, Málaga, Not set

Investigational Site Number 724001, Palma De Mallorca, Not set

Investigational Site Number 724008, Sevilla, Not set

Investigational Site Number 724010, Valencia, Not set

Investigational Site Number 724007, Zaragoza, Not set

Investigational Site Number 826002, Glasgow, Not set

Investigational Site Number 826005, Leeds, Not set

Investigational Site Number 826001, Manchester, Not set

Investigational Site Number 826006, Wolverhampton, Not set

Conditions: Squamous Cell Lung Cancer

Learn More ›

Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours

NCT00809133

Completed

The main purpose of this study is to assess the optimum dose of the following medications when they are given together: * BIBW 2992 and paclitaxel (Taxol) * BIBW 2992 and paclitaxel and bevacizumab (Avastin) * BIBW 2992 and carboplatin * BIBW 2992 and paclitaxel and carboplatin The effect of the different drug combinations will also be assessed.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/16/2016

Locations: 1200.12.4402 Boehringer Ingelheim Investigational Site, London, Not set +1 locations

Conditions: Neoplasms

Learn More ›

International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel

NCT02051868

Unknown

Anal cancer is a relatively uncommon disease and there is currently no standard chemotherapy treatment for patients with inoperable locally recurrent or metastatic disease. The aim of this phase II study is compare two well known and largely used chemotherapy regimens - Cisplatin plus 5-fluorouracil vs Carboplatin plus Paclitaxel. The result of this study will set a standard of care for this disease and provide useful information for future Phase III trials.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

11/03/2015

Locations: Laura Gagnon, Boston, Massachusetts +2 locations

Conditions: Squamous Cell Carcinoma of the Anus

Learn More ›

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

NCT00317408

Unknown

RATIONALE: Giving combination chemotherapy and total-body irradiation before a peripheral stem cell transplant that uses the patient's or a donor's stem cells, helps stop both the growth of cancer cells and the patient's immune system from rejecting the stem cells. When the stem cells are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving combination chemotherapy and total-body irradiation followed by a stem... Read More

Gender:

ALL

Ages:

21 years and below

Trial Updated:

09/24/2015

Locations: St. Anna Children's Hospital, Vienna, Not set +97 locations

St. Anna Children's Hospital, Vienna, Not set

U.Z. Gasthuisberg, Leuven, Not set

University Hospital Brno, Brno, Not set

Charles University Hospital, Prague 5, Not set

Centre Leon Berard, Lyon, Not set

Kinderklinik - Universitaetsklinikum Aachen, Aachen, Not set

Klinikum Augsburg, Augsburg, Not set

Helios Klinikum Berlin, Berlin, Not set

Charite University Hospital - Campus Virchow Klinikum, Berlin, Not set

Evangelisches Krankenhauus Bielfeld, Biefeld, Not set

Kinderklinik der Universitaet Bonn, Bonn, Not set

Staedtisches Klinikum - Howedestrase, Braunschweig, Not set

Klinikum Bremen-Mitte, Bremen, Not set

Klinikum Chemnitz gGmbH, Chemnitz, Not set

Kliniken der Stadt Koeln gGmbH - Kinderkrankenhaus Riehl, Cologne, Not set

Children's Hospital, Cologne, Not set

Carl - Thiem - Klinkum Cottbus, Cottbus, Not set

Vestische Kinderklinik, Datteln, Not set

Klinikum Dortmund, Dortmund, Not set

Universitatsklinikum Carl Gustav Carus, Dresden, Not set

Universitaetsklinikum Duesseldorf, Duesseldorf, Not set

Helios Klinikum Erfurt, Erfurt, Not set

Universitaets - Kinderklinik, Erlangen, Not set

Universitaetsklinikum Essen, Essen, Not set

Klinikum der J.W. Goethe Universitaet, Frankfurt, Not set

Universitaetskinderklinik - Universitaetsklinikum Freiburg, Freiburg, Not set

Kinderklinik, Giessen, Not set

Universitaetsklinikum Goettingen, Goettingen, Not set

Klinik und Poliklinik Fuer Kinder-und Jugendmedizin - Universitaetsklinikum Greifswald, Greifswald, Not set

University Medical Center Hamburg - Eppendorf, Hamburg, Not set

Medizinische Hochschule Hannover, Hannover, Not set

Universitaets-Kinderklinik Heidelberg, Heidelberg, Not set

Gemeinschaftskrankenhaus, Herdecke, Not set

Universitaetsklinikum des Saarlandes, Homburg, Not set

Universitaets - Kinderklinik, Jena, Not set

Staedtisches Klinikum Karlsruhe gGmbH, Karlsruhe, Not set

Klinikum Kassel, Kassel, Not set

University Hospital Schleswig-Holstein - Kiel Campus, Kiel, Not set

Klinikum Kemperhof Koblenz, Koblenz, Not set

Klinikum Krefeld GmbH, Krefeld, Not set

Universitaets - Kinderklinik, Leipzig, Not set

St. Annastift Krankenhaus, Ludwigshafen, Not set

Universitaets - Kinderklinik - Luebeck, Luebeck, Not set

Universitatsklinikum der MA, Magdeburg, Not set

Johannes Gutenberg University, Mainz, Not set

Staedtisches Klinik - Kinderklinik, Mannheim, Not set

Universitaets - Kinderklinik, Marburg, Not set

Klinikum Minden, Minden, Not set

Klinik und Poliklinik fuer Kinder und Jugendmedizin - Universitaetsklinikum Muenster, Muenster, Not set

Krankenhaus Muenchen Schwabing, Munich, Not set

Dr. von Haunersches Kinderspital der Universitaet Muenchen, Munich, Not set

Kinderklinik Kohlhof, Neunkirchen, Not set

Cnopf'sche Kinderklinik, Nuremberg, Not set

Klinikum Oldenburg, Oldenburg, Not set

Klinik St. Hedwig-Kinderklinik, Regensburg, Not set

Kinderklinik - Universitaetsklinikum Rostock, Rostock, Not set

Saarbrucker Winterbergkliniken, Saarbrucken, Not set

Klinikum Schwerin, Schwerin, Not set

Kinderklink Siegen Deutsches Rotes Kreuz, Siegen, Not set

Johanniter-Kinderklinik, St. Augustin, Not set

Olgahospital, Stuttgart, Not set

Krankenanstalt Mutterhaus der Borromaerinnen, Trier, Not set

Universitaetsklinikum Tuebingen, Tuebingen, Not set

Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm, Ulm, Not set

Dr. Horst-Schmidt-Kliniken, Wiesbaden, Not set

Universitaets - Kinderklinik Wuerzburg, Wuerzburg, Not set

Helios Kliniken Wuppertal University Hospital, Wuppertal, Not set

Our Lady's Hospital for Sick Children Crumlin, Dublin, Not set

Azienda Ospedaliera di Padova, Padova, Not set

Erasmus MC - Sophia Children's Hospital, Rotterdam, Not set

Akademia Medyczna im. Piastow Slaskich, Wroclaw, Not set

Goeteborg University, Goeteborg, Not set

Kantonspital Aarau, Aarau, Not set

Universitaets-Kinderspital beider Basel, Basel, Not set

Ospedale "la Carita", Locarno, Locarno, Not set

Kinderspital Luzern, Lucerne 16, Not set

Ostschweizer Kinderspital, St. Gallen, Not set

University Children's Hospital, Zurich, Not set

Birmingham Children's Hospital, Birmingham, England

Institute of Child Health at University of Bristol, Bristol, England

Addenbrooke's Hospital, Cambridge, England

Leeds Cancer Centre at St. James's University Hospital, Leeds, England

Leicester Royal Infirmary, Leicester, England

Royal Liverpool Children's Hospital, Alder Hey, Liverpool, England

Middlesex Hospital, London, England

Great Ormond Street Hospital for Children, London, England

Royal Manchester Children's Hospital, Manchester, England

Sir James Spence Institute of Child Health at Royal Victoria Infirmary, Newcastle-Upon-Tyne, England

Queen's Medical Centre, Nottingham, England

Oxford Radcliffe Hospital, Oxford, England

Children's Hospital - Sheffield, Sheffield, England

Southampton General Hospital, Southampton, England

Royal Marsden - Surrey, Sutton, England

Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland

Royal Aberdeen Children's Hospital, Aberdeen, Scotland

Royal Hospital for Sick Children, Edinburgh, Scotland

Royal Hospital for Sick Children, Glasgow, Scotland

Childrens Hospital for Wales, Cardiff, Wales

Conditions: Lymphoma

Learn More ›

Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer

NCT00850577

Terminated

The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with carboplatin and paclitaxel in the treatment of chemonaive subjects with recurrent or advanced non-squamous NSCLC

Gender:

ALL

Ages:

18 years and above

Trial Updated:

09/23/2015

Locations: Acrc/Arizona Clinical Research Center, Inc., Tucson, Arizona +54 locations

Acrc/Arizona Clinical Research Center, Inc., Tucson, Arizona

Sharp Clinical Oncology Research, San Diego, California

Cancer Institute Of Florida, Orlando, Florida

Palm Beach Cancer Institute, West Palm Beach, Florida

Clintell, Inc., Skokie, Illinois

Cancer Center Of Kansas, Wichita, Kansas

Kentucky Cancer Clinic, Hazard, Kentucky

Annapolis Oncology Center, Annapolis, Maryland

Meritus Center For Clinical Research, Hagerstown, Maryland

North Mississippi Hematology And Oncology Associates, Ltd, Tupelo, Mississippi

Piedmont Hematology Oncology Associates, Pllc, Winston-salem, North Carolina

North Canton Medical Clinic Center, Canton, Ohio

Kaiser Permanente Oncology/Hematology, Portland, Oregon

Guthrie Clinic, Ltd, Sayre, Pennsylvania

Rhode Island Hospital, Providence, Rhode Island

Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina

Cancer Center At Cookeville Regional Medical Center, Cookeville, Tennessee

University Of Tennessee Cancer Institute, Memphis, Tennessee

Blue Ridge Cancer Care, Christiansburg, Virginia

Providence Western Washington Oncology, Lacey, Washington

Local Institution, Fortaleza, Ceara

Local Institution, Belo Horizonte, Minas Gerais

Local Institution, Porto Alegre, Rio Grande Do Sul

Local Institution, Barretos, Sao Paulo

Local Institution, Rio De Janeiro, Not set

Local Institution, Sao Paulo, Not set

Local Institution, Marseille Cedex 20, Not set

Local Institution, Paris, Not set

Local Institution, Rennes Cedex 9, Not set

Local Institution, Toulouse Cedex 9, Not set

Local Institution, Tours Cedex, Not set

Local Institution, Meldola (Fc), Not set

Local Institution, Ravenna, Not set

Local Institution, Rimini, Not set

Local Institution, Roma, Not set

Local Institution, Terni, Not set

Local Institution, Bialystok, Not set

Local Institution, Gdansk, Not set

Local Institution, Otwock, Not set

Local Institution, Poznan, Not set

Local Institution, Szczecin, Not set

Local Institution, Warsaw, Not set

Local Institution, Chelyabinsk, Not set

Local institution, Ivanovo, Not set

Local Institution, Moscow, Not set

Local Institution, Port Elizabeth, Eastern Cape

Local Institution, Pretoria, Gauteng

Local Institution, Cape Town, Western Cape

Local Institution, Rondebosch, Western Cape

Local Institution, Manchester, Greater Manchester

Local Institution, Leeds, West Yorkshire

Conditions: Non-small Cell Lung Cancer (NSCLC)

Learn More ›